Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05219500 · ClinicalTrials.gov registry record · Phase 2
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Fusion Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
- 2
- Study locations
NCT05219500: Active Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Fusion Pharmaceuticals.
NCT05219500 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is active but no longer recruiting, run by Fusion Pharmaceuticals. The registered enrollment target is 115 participants, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (41% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05219500, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is active but no longer recruiting, sponsored by Fusion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
- 2
- Study locations
Study Summary
The treatment regimen will consist of 4 doses of FPI-2265
Primary Outcome
Frequency and proportion of participants with PSA50, defined as ≥ 50% decline in PSA level by 12-weeks after the first treatment.
Conditions Studied
Interventions
- DRUG FPI-2265
Study Locations (2)
Nebraska
- XCancer Omaha/Urology Cancer Center - Omaha
Texas
- Excel Diagnostics and Nuclear Oncology Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
What the registry record for NCT05219500 still lists
NCT05219500 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which FPI-2265 is the first listed.
NCT05219500 reports a single indexed study location in Nebraska, Texas.
Frequently Asked Questions
What is clinical trial NCT05219500 about?
NCT05219500 is a clinical study titled "Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).". The treatment regimen will consist of 4 doses of FPI-2265
What is the current status of trial NCT05219500?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2021-12-16. Estimated completion is 2026-07-31.
What conditions does trial NCT05219500 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT05219500?
The interventions under investigation include: FPI-2265 (DRUG).
Who is sponsoring clinical trial NCT05219500?
This trial is sponsored by Fusion Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05219500 being conducted?
This trial has 2 study locations across Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05219500's enrollment target sits among peer trials
115 25th of 69 higher than 45 of 69 other Metastatic Castration-Resistant Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
RECRUITING · Phase 2
-
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
RECRUITING · Phase 2
-
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI